KRAS gene amplification in colorectal cancer and impact on response to EGFR‐targeted therapy

@article{Valtorta2013KRASGA,
  title={KRAS gene amplification in colorectal cancer and impact on response to EGFR‐targeted therapy},
  author={E. Valtorta and Sandra Misale and A. Sartore-Bianchi and Iris D. Nagtegaal and F. Paraf and C. Lauricella and V. Dimartino and Sebastijan Hobor and B. Jacobs and C. Ercolani and S. Lamba and E. Scala and S. Veronese and P. Laurent-Puig and S. Siena and S. Tejpar and M. Mottolese and C. Punt and M. Gambacorta and A. Bardelli and F. Nicolantonio},
  journal={International Journal of Cancer},
  year={2013},
  volume={133}
}
KRAS mutations are the most common oncogenic event in colorectal cancer (CRC) progression and their occurrence is associated with lack of response to anti epidermal growth factor receptor (EGFR) targeted therapies. Using preclinical models and patients' samples we recently reported that the emergence of KRAS mutations but also KRAS amplification is associated with acquired resistance to the EGFR inhibitors cetuximab or panitumumab. We reasoned that KRAS amplification may also be responsible for… Expand
144 Citations
Mutant KRAS as a critical determinant of the therapeutic response of colorectal cancer
  • 74
Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer.
  • 472
  • PDF
New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: do all roads lead to RAS?
  • 64
  • PDF
Changes in Colorectal Carcinoma Genomes under Anti-EGFR Therapy Identified by Whole-Genome Plasma DNA Sequencing
  • 138
  • Highly Influenced
  • PDF
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 29 REFERENCES
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer
  • 1,336
  • PDF
Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer.
  • A. Bardelli, S. Siena
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2010
  • 610
K-ras mutations and benefit from cetuximab in advanced colorectal cancer.
  • 3,160
  • PDF
PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab.
  • 435
  • Highly Influential
  • PDF
Evaluation of Kras Gene Mutation and Copy Number Gain in Non-small Cell Lung Cancer
  • 37
Oncogenic Activating Mutations Are Associated with Local Copy Gain
  • 55
  • PDF
...
1
2
3
...